Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis
Abstract
Background: ASCOLT compared adjuvant aspirin versus (vs) placebo in 1587 patients with colorectal cancer (CRC) and reported no significant improvement in disease-free survival (DFS). Subsequently, two randomised controlled trials (RCTs) reported benefit of adjuvant aspirin in CRC patients with somatic PI3K-related mutations.
Methods: The ASCOLT Translational Research (TR) study was a preplanned subgroup analysis by PIK3CA mutation status and COX-2 overexpression, and an exploratory analysis including PTEN mutation status. Among 778 participants who commenced study medication, tissue was evaluable for targeted next generation sequencing of PIK3CA and PTEN in 289 tumours and by Sanger sequencing for PIK3CA exon 9 or 20 (9/20) mutations in a further 108. PTGS2/COX-2 expression was assessed by immunohistochemistry in 450. Hazard ratio (HR) and 95% confidence intervals (CI) for DFS of aspirin vs placebo in subgroups were assessed in Cox models. A systematic review of completed RCTs of adjuvant aspirin in CRC patients with PIK3CA mutations was also undertaken.
Registration: NCT00565708 and ACTRN12614000513617.
Findings: Among 397 patients with tumour assessable for PIK3CA, there were 80 recurrences, 40 deaths and 86 DFS events after 5 years follow-up. Among 69 (17%) with PIK3CA mutations (any exon), there were 8 vs 8 DFS events on placebo vs aspirin (HR 0.93 (95% CI 0.35-2.47); in 45 (11%) with exon 9/20 mutations, 7 vs 4 events (HR 0.72 (95% CI 0.21-2.46) and in 84 (21%) with…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,587 participants or records.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.